Targeted delivery of a suicide gene to human colorectal tumors by a conditionally replicating vaccinia virus

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Gene Therapy

• Publication date

  2008-05-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/gt.2008.82PMID 18480846
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Modified vaccinia virus Ankara as a vector for suicide gene therapy

  2008cited by this paper
• Vaccinia virus preferentially infects and controls human and murine ovarian tumors in mice

  2007cited by this paper
• Cancer Statistics, 2007

  2007cited by this paper
• Suicide gene therapy of human colon carcinoma xenografts using an armed oncolytic adenovirus expressing carboxypeptidase G2.

  2007cited by this paper
• Frequency of Adverse Events after Vaccination with Different Vaccinia Strains

  2006cited by this paper
• Correction: Routine HIV Testing in Botswana: A Population-Based Study on Attitudes, Practices, and Human Rights Concerns

  2006cited by this paper
• Reovirus - possible therapy of cancer.

  2006cited by this paper
• Fighting cancer with vaccinia virus: teaching new tricks to an old dog.

  2005cited by this paper
• Surgical therapy for metastatic disease to the liver.

  2005cited by this paper
• 5-Fluorouracil and gemcitabine potentiate the efficacy of oncolytic herpes viral gene therapy in the treatment of pancreatic cancer

  2005cited by this paper
• Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986.

  2005cited by this paper
• Intravenous and Isolated Limb Perfusion Delivery of Wild Type and a Tumor-Selective Replicating Mutant Vaccinia Virus in Nonhuman Primates

  2005cited by this paper
• Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment.

  2004cited by this paper
• A tumor-targeted and conditionally replicating oncolytic adenovirus vector expressing TRAIL for treatment of liver metastases.

  2004cited by this paper
• 5-Fluorouracil: mechanisms of action and clinical strategies

  2003cited by this paper
• Dr. Gary J. Becker Young Investigator Award: intraarterial adenovirus for metastatic gastrointestinal cancer: activity, radiographic response, and survival.

  2003cited by this paper
• Bystander effect in suicide gene therapy is directly proportional to the degree of gap junctional intercellular communication in esophageal cancer.

  2003cited by this paper
• Enzyme-activated Prodrug Therapy Enhances Tumor-specific Replication of Adenovirus Vectors.

  2002cited by this paper
• Cytolytic viruses as potential anti-cancer agents.

  2002cited by this paper
• Molecular therapies for colorectal cancer metastatic to the liver.

  2002cited by this paper
• Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints.

  2002cited by this paper
• Safety of Local Delivery of Low- and Intermediate-Dose Adenovirus Gene Transfer Vectors to Individuals with a Spectrum of Morbid Conditions

  2002cited by this paper
• Multimodality therapy with a replication-conditional herpes simplex virus 1 mutant that expresses yeast cytosine deaminase for intratumoral conversion of 5-fluorocytosine to 5-fluorouracil.

  2001cited by this paper
• Vaccinia as a vector for tumor-directed gene therapy: Biodistribution of a thymidine kinase-deleted mutant

  2000cited by this paper
• Complex interactions between the replicating oncolytic effect and the enzyme/prodrug effect of vaccinia-mediated tumor regression

  2000cited by this paper
• Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.

  2000cited by this paper
• In vivo cancer gene therapy by adenovirus-mediated transfer of a bifunctional yeast cytosine deaminase/uracil phosphoribosyltransferase fusion gene.

  2000cited by this paper
• Conditionally replicating herpes vectors for cancer therapy.

  2000cited by this paper
• Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.

  2000cited by this paper
• Thymidine Kinase-Deleted Vaccinia Virus Expressing Purine Nucleoside Phosphorylase as a Vector for Tumor-Directed Gene Therapy

  1999cited by this paper
• Superiority of yeast over bacterial cytosine deaminase for enzyme/prodrug gene therapy in colon cancer xenografts.

  1999cited by this paper
• Regional versus systemic delivery of recombinant vaccinia virus as suicide gene therapy for murine liver metastases.

  1999cited by this paper
• Enzyme/Prodrug Therapy for Head and Neck Cancer Using a Catalytically Superior Cytosine Deaminase

  1999cited by this paper
• Colorectal cancer.

  1999cited by this paper
• Tumor-specific gene delivery using recombinant vaccinia virus in a rabbit model of liver metastases.

  1999cited by this paper
• Concomitant expression of E. coli cytosine deaminase and uracil phosphoribosyltransferase improves the cytotoxicity of 5-fluorocytosine.

  1998cited by this paper
• Regulation of angiogenesis by hypoxic stress: from solid tumours to the ovarian follicle

  1997cited by this paper
• Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexins.

  1996cited by this paper
• Replicating viruses as selective cancer therapeutics.

  1996cited by this paper
• Applications of pox virus vectors to vaccination: an update.

  1996cited by this paper
• Directed cytokine expression in tumour cells in vivo using recombinant vaccinia virus.

  1994cited by this paper
• Colorectal cancer

  1993cited by this paper
• NYVAC: a highly attenuated strain of vaccinia virus.

  1992cited by this paper
• Introduction of foreign DNA into the vaccinia virus genome by in vitro ligation: recombination-independent selectable cloning vectors.

  1992cited by this paper
• Comparison of the virulence of wild-type thymidine kinase (tk)-deficient and tk+ phenotypes of vaccinia virus recombinants after intranasal inoculation of mice.

  1991cited by this paper
• Inhibition of liver metastases in nude mice by the combined action of 5-fluorouracil and interferon.

  1990cited by this paper
• Vaccinia virus‐mediated damage of murine ovaries and protection by virus‐expressed interleukin‐2

  1990cited by this paper
• Cancer statistics

  1989cited by this paper
• Single-step purification of polypeptides expressed in Escherichia coli as fusions with glutathione S-transferase.

  1988cited by this paper
• Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype

  1985cited by this paper
• Expression of rabies virus glycoprotein from a recombinant vaccinia virus

  1984cited by this paper
• Monoclonal antibodies to estrophilin: probes for the study of estrogen receptors.

  1980cited by this paper
• L'Uretere Artificiale

  1975cited by this paper

• Progress in the research and development of oncolytic virus therapies.

  2026cites this paper
• Oncolytic Viruses as a Novel Therapeutic Approach for Colorectal Cancer: Mechanisms, Current Advances, and Future Directions

  2025cites this paper
• TG6002 oncolytic vaccinia virus and chemotherapy synergy: a promising strategy for pancreatic ductal adenocarcinoma

  2025cites this paper
• Colorectal Cancer Hepatic Metastasis Modeling by Advanced 3D Bioprinting Allows Demonstration of Oncolytic Viral Chemotherapeutic Delivery

  2025cites this paper
• Oncolytic Vesicular Stomatitis Virus: Optimisation Strategies for Anti-Cancer Therapies.

  2024cites this paper
• Vaccinia virus-mediated oncolytic immunotherapy: Emerging strategies for gastrointestinal cancer treatment at dawn.

  2024cites this paper
• The αvβ6 integrin specific virotherapy, Ad5NULL-A20.FCU1, selectively delivers potent “in-tumour” chemotherapy to pancreatic ductal adenocarcinoma

  2024cites this paper
• Immunotherapeutic Strategies for the Treatment of Glioblastoma: Current Challenges and Future Perspectives

  2024cites this paper
• Molecular insights and promise of oncolytic virus based immunotherapy.

  2024cites this paper
• Mediation of antitumor activity by AZD4820 oncolytic vaccinia virus encoding IL-12

  2024cites this paper
• Viral/Non-Viral Vectors in DNA/RNA Delivery Technology

  2024cites this paper
• Stable Biotherapeutic Penetration Screening in Critically Small Colorectal Metastatic Cancer Biopsies Allows for Oncolytic Virus‐Delivered Chemotherapeutic Response Assessment through 3D Bioprinted Organoid Expansion

  2024cites this paper
• [Oncolytic viruses: Actors and deliverers of therapeutic proteins against tumors].

  2023cites this paper
• Global trends of Vaccinia oncolytic virus therapy over the past two decades: Bibliometric and visual analysis

  2023influential citation
• Oncolytic virotherapy with intratumoral injection of vaccinia virus TG6002 and 5-fluorocytosine administration in dogs with malignant tumors

  2023cites this paper
• The employment of vaccinia virus for colorectal cancer treatment: A review of preclinical and clinical studies

  2022cites this paper
• Gastric Cancer and Viruses: A Fine Line between Friend or Foe

  2022cites this paper
• Comprehensive assessment on the applications of oncolytic viruses for cancer immunotherapy

  2022cites this paper
• Strategies for Advanced Oncolytic Virotherapy: Current Technology Innovations and Clinical Approaches

  2022cites this paper
• Human SNF5 arming of double-deleted vaccinia virus shows oncolytic and cytostatic activity against central nervous system atypical teratoid/rhabdoid tumor cells

  2020cites this paper
• Immunotherapy-Based Approaches for Treatment of Oral and Oropharyngeal Cancers

  2020cites this paper
• Target Therapy With Vaccinia Virus Harboring IL-24 For Human Breast Cancer

  2020cites this paper
• Safety, biodistribution and viral shedding of oncolytic vaccinia virus TG6002 administered intravenously in healthy beagle dogs

  2020cites this paper
• Fluorescent Tagged Vaccinia Virus Genome Allows Rapid and Efficient Measurement of Oncolytic Potential and Discovery of Oncolytic Modulators

  2020cites this paper
• Assessing and Overcoming Resistance Phenomena against a Genetically Modified Vaccinia Virus in Selected Cancer Cell Lines

  2020cites this paper
• Preclinical Evaluation of the Oncolytic Vaccinia Virus TG6002 by Translational Research on Canine Breast Cancer

  2020cites this paper
• High Oncolytic Activity of a Double-Deleted Vaccinia Virus Copenhagen Strain against Malignant Pleural Mesothelioma

  2020cites this paper
• IL-24-Armed Oncolytic Vaccinia Virus Exerts Potent Antitumor Effects via Multiple Pathways in Colorectal Cancer

  2020cites this paper
• Deletion of Apoptosis Inhibitor F1L in Vaccinia Virus Increases Safety and Oncolysis for Cancer Therapy

  2019cites this paper
• Combinatory effects of vaccinia virus VG9 and the STAT3 inhibitor Stattic on cancer therapy

  2019cites this paper
• The Enhanced Tumor Specificity of TG6002, an Armed Oncolytic Vaccinia Virus Deleted in Two Genes Involved in Nucleotide Metabolism

  2019influential citation
• Oncolytic Viruses for Cancer Therapy: Barriers and Recent Advances

  2019cites this paper
• Virotherapy: Current Trends and Future Prospects for Treatment of Colon and Rectal Malignancies

  2019cites this paper
• Evaluation of the effects of oncolytic vaccinia virus on colorectal liver metastases in cell lines and in organotypic cultures

  2019cites this paper
• Oncolytic cancer therapy with a vaccinia virus strain.

  2018cites this paper
• Oncolytic viruses sensitize human tumor cells for NY-ESO-1 tumor antigen recognition by CD4+ effector T cells.

  2018cites this paper
• Current Strategies to Enhance Anti-Tumour Immunity

  2018cites this paper
• Vaccinia Virus Shuffling: deVV5, a Novel Chimeric Poxvirus with Improved Oncolytic Potency

  2018cites this paper
• Progress in gene therapy using oncolytic vaccinia virus as vectors

  2018cites this paper
• Oncolytic properties of non-vaccinia poxviruses

  2018influential citation
• Advance on research of oncolytic vaccinia virus inhibits tumor cells

  2017cites this paper
• Genetically Engineered Vaccinia Viruses As Agents for Cancer Treatment, Imaging, and Transgene Delivery

  2017cites this paper
• Cowpox Virus: A New and Armed Oncolytic Poxvirus

  2017cites this paper
• Immune Checkpoint Blockade, Immunogenic Chemotherapy or IFN-α Blockade Boost the Local and Abscopal Effects of Oncolytic Virotherapy.

  2017cites this paper
• immunogenicity of oncolytic vaccinia viruses JX-gFP and Tg6002 in a human melanoma in vitro model: studying immunogenic cell death, dendritic cell maturation and interaction with cytotoxic T lymphocytes

  2017influential citation
• Chemovirotherapy of Pancreatic Adenocarcinoma by Combining Oncolytic Vaccinia Virus GLV-1h68 with nab-Paclitaxel Plus Gemcitabine

  2017cites this paper
• Immunogenicity of oncolytic vaccinia viruses JX-GFP and TG6002 in a human melanoma in vitro model: studying immunogenic cell death, dendritic cell maturation and interaction with cytotoxic T lymphocytes

  2017cites this paper
• Targeting Nucleotide Biosynthesis: A Strategy for Improving the Oncolytic Potential of DNA Viruses

  2017influential citation
• Classification of current anticancer immunotherapies

  2017cites this paper
• Vectorized gene therapy of liver tumors: proof-of-concept of TG4023 (MVA-FCU1) in combination with flucytosine

  2016cites this paper
• Trial Watch—Oncolytic viruses and cancer therapy

  2016cites this paper
• Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death -1 (PD-1) allows their intratumoral delivery and an improved tumor-growth inhibition

  2016cites this paper
• Polymeric Cups for Cavitation-mediated Delivery of Oncolytic Vaccinia Virus

  2016influential citation
• Oncolytic and immunologic cancer therapy with GM-CSF-armed vaccinia virus of Tian Tan strain Guang9.

  2016cites this paper
• Isolated limb perfusion with melphalan, tumour necrosis factor‐alpha and oncolytic vaccinia virus improves tumour targeting and prolongs survival in a rat model of advanced extremity sarcoma

  2015cites this paper
• The Evolution of Poxvirus Vaccines

  2015cites this paper
• Oncolytic virotherapy with an armed vaccinia virus in an orthotopic model of renal carcinoma is associated with modification of the tumor microenvironment

  2015cites this paper
• Oncolytic viruses: a new class of immunotherapy drugs

  2015cites this paper
• Trial Watch:

  2014cites this paper
• Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy

  2014cites this paper
• Classification of current anticancer immunotherapies

  2014cites this paper
• Oncolytic vaccinia virotherapy for endometrial cancer.

  2014cites this paper
• Anticancer gene transfer for cancer gene therapy.

  2014cites this paper
• Vaccinia Virus Outperforms a Panel of Other Poxviruses as a Potent Oncolytic Agent for the Control of Head and Neck Squamous Cell Carcinoma Cell Lines

  2013cites this paper
• Chemovirotherapy of malignant melanoma with a targeted and armed oncolytic measles virus.

  2013cites this paper
• Trial watch

  2013cites this paper
• Intrahepatic Application of Suicide Gene-Armed Measles Virotherapeutics: A Safety Study in Transgenic Mice and Rhesus Macaques

  2013cites this paper
• New viruses for cancer therapy: meeting clinical needs

  2013cites this paper
• Incorporation of the B18R gene of vaccinia virus into an oncolytic herpes simplex virus improves antitumor activity.

  2012cites this paper
• Enhancing the oncolytic efficacy of vaccinia virus by mutagenic augmentation of EEV production

  2012cites this paper
• Potentiating the Oncolytic Efficacy of Poxviruses

  2012cites this paper
• Annals of Surgery Isolated limb perfusion with melphalan, tumour necrosis factor-alpha and oncolytic vaccinia virus delays tumour growth and prolongs survival in a rat model of locally advanced extremity sarcoma

  2012cites this paper
• Bugs and drugs: oncolytic virotherapy in combination with chemotherapy.

  2012cites this paper
• Functional hyper-IL-6 from vaccinia virus-colonized tumors triggers platelet formation and helps to alleviate toxicity of mitomycin C enhanced virus therapy

  2012cites this paper
• Selectivity and Efficiency of Late Transgene Expression by Transcriptionally Targeted Oncolytic Adenoviruses Are Dependent on the Transgene Insertion Strategy

  2011cites this paper
• Comparative Analysis of Enzyme and Pathway Engineering Strategies for 5FC-Mediated Suicide Gene Therapy Applications

  2011cites this paper
• The Oncolytic Poxvirus JX-594 Selectively Replicates in and Destroys Cancer Cells Driven by Genetic Pathways Commonly Activated in Cancers

  2011cites this paper
• Oncolytic vaccinia virus for the treatment of cancer

  2011cites this paper
• Immunotherapeutic potential of oncolytic vaccinia virus

  2011cites this paper
• Oncolytic viruses: a step into cancer immunotherapy

  2011cites this paper
• Virus Adaptation and Treatment Oncolytic viruses : a step into cancer immunotherapy

  2011cites this paper
• Replication-competent adenovirus 11p vector as a new oncolytic agent

  2011cites this paper
• Enhancing VSV oncolytic activity with an improved cytosine deaminase suicide gene strategy

  2011cites this paper
• Oncolytic Herpes simplex virus expressing yeast cytosine deaminase: relationship between viral replication, transgene expression, prodrug bioactivation

  2011cites this paper
• Cytokine-armed vaccinia virus infects the mesothelioma tumor microenvironment to overcome immune tolerance and mediate tumor resolution

  2010cites this paper
• Locoregional intravascular viral therapy of cancer: precision guidance for Paris's arrow?

  2010cites this paper
• Adenoviral Gene Therapy for Advanced Head and Neck Cancer

  2010cites this paper
• Molecular Imaging of Biological Gene Delivery Vehicles for Targeted Cancer Therapy: Beyond Viral Vectors

  2010cites this paper
• Intelligent Design: Combination Therapy With Oncolytic Viruses.

  2010cites this paper
• Oncolytic vaccinia virus: a theranostic agent for cancer

  2010cites this paper
• Assessment and development of adenovirus type 11 for cancer therapy

  2010cites this paper
• Targeted Chemotherapy for Head and Neck Cancer with a Chimeric Oncolytic Adenovirus Coding for Bifunctional Suicide Protein FCU1

  2010cites this paper
• Oncolytic Viruses for Cancer Therapy: Overcoming the Obstacles

  2010cites this paper
• TRAIL Gene-Armed Oncolytic Poxvirus and Oxaliplatin Can Work Synergistically against Colorectal Cancer

  2010cites this paper
• Approaches for improving the safety and efficacy of adenoviral gene therapy

  2010cites this paper
• Enhanced tumor therapy using vaccinia virus strain GLV-1h68 in combination with a β-galactosidase-activatable prodrug seco-analog of duocarmycin SA

  2010cites this paper
• Oncolytic vaccinia virus: a silver bullet?

  2010cites this paper
• Antiangiogenic Arming of an Oncolytic Vaccinia Virus Enhances Antitumor Efficacy in Renal Cell Cancer Models

  2009cites this paper
• Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer

  2009cites this paper
• In Vivo Cellular Imaging for Translational Medical Research.

  2009cites this paper